312 related articles for article (PubMed ID: 8910322)
41. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
42. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
44. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
[TBL] [Abstract][Full Text] [Related]
45. Kinetics of factor VIII-von Willebrand factor association.
Vlot AJ; Koppelman SJ; Meijers JC; Dama C; van den Berg HM; Bouma BN; Sixma JJ; Willems GM
Blood; 1996 Mar; 87(5):1809-16. PubMed ID: 8634427
[TBL] [Abstract][Full Text] [Related]
46. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
47. Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane.
Ahmad SS; Walsh PN
Biochemistry; 2005 Oct; 44(42):13858-65. PubMed ID: 16229474
[TBL] [Abstract][Full Text] [Related]
48. Characterisation of an antibody specific for coagulation factor VIII that enhances factor VIII activity.
Takeyama M; Nogami K; Matsumoto T; Soeda T; Suzuki T; Hattori K; Shima M
Thromb Haemost; 2010 Jan; 103(1):94-102. PubMed ID: 20062922
[TBL] [Abstract][Full Text] [Related]
49. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII.
Saenko EL; Loster K; Josic D; Sarafanov AG
Thromb Res; 1999 Dec; 96(5):343-54. PubMed ID: 10605949
[TBL] [Abstract][Full Text] [Related]
50. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.
Foster PA; Fulcher CA; Marti T; Titani K; Zimmerman TS
J Biol Chem; 1987 Jun; 262(18):8443-6. PubMed ID: 3110147
[TBL] [Abstract][Full Text] [Related]
51. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
J Biol Chem; 1988 Apr; 263(11):5230-4. PubMed ID: 2895765
[TBL] [Abstract][Full Text] [Related]
52. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
53. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
54. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.
Fischer BE; Kramer G; Mitterer A; Grillberger L; Reiter M; Mundt W; Dorner F; Eibl J
Thromb Res; 1996 Oct; 84(1):55-66. PubMed ID: 8885147
[TBL] [Abstract][Full Text] [Related]
55. Coagulant properties of hybrid human/porcine factor VIII molecules.
Lollar P; Parker ET; Fay PJ
J Biol Chem; 1992 Nov; 267(33):23652-7. PubMed ID: 1429706
[TBL] [Abstract][Full Text] [Related]
56. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
57. Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
Aly AM; Hoyer LW
J Clin Invest; 1992 May; 89(5):1382-7. PubMed ID: 1569181
[TBL] [Abstract][Full Text] [Related]
58. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.
d'Oiron R; Lavergne JM; Lavend'homme R; Benhida A; Bordet JC; Negrier C; Peerlinck K; Vermylen J; Saint-Remy JM; Jacquemin M
Blood; 2004 Jan; 103(1):155-7. PubMed ID: 12969981
[TBL] [Abstract][Full Text] [Related]
59. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
60. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Vlot AJ; Koppelman SJ; van den Berg MH; Bouma BN; Sixma JJ
Blood; 1995 Jun; 85(11):3150-7. PubMed ID: 7756647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
